Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Sickle Cell Treatment & Ten Other Drugs Win English Funding Approval

Executive Summary

Health technology assessment body NICE has also issued guidances rejecting three products.

You may also be interested in...



BioCryst & Celgene Suffer English Funding Setback For Rare Disease Drugs

Orladeyo and Inrebic have been approved in Great Britain but they will not be available under the National Health Service unless their manufacturers can convince the health technology assessment body, NICE, that their products are cost-effective.

AdvaMed Launches Ethics Code To Meet ‘Business & Market Realities’ In India

Industry group AdvaMed says its Indian code on interactions between medtech companies and health care professionals is a first for the country.

EMA Tells Marketing Authorization Applicants How To Run Registry-Based Studies

Advice on the acceptability of registry-based studies as a source of evidence for regulatory purposes is included in new guidance from the European Medicines Agency.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel